Clinical trials / Massachusetts
Psychedelic and ketamine trials recruiting in Massachusetts
7 trials registered on ClinicalTrials.gov were recruiting at one or more sites in Massachusetts on 26 Oct 2026. By substance: Ketamine / esketamine 3, Psilocybin 3, MDMA 1. By condition: depression 4, opioid use disorder 1, cancer and end-of-life distress 1.
From the ClinicalTrials.gov registry (US National Library of Medicine), read through its public API on 26 Oct 2026: studies marked as recruiting whose interventions name the substance. Titles, sponsors, phases, conditions and sites are the registry's own entries, written by the sponsors. We have not vetted any trial, and recruiting status changes; the registry record and the study team have the current eligibility rules.
Phase 3Ketamine / esketamineNCT07227454
A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder (AVENUE)
- Conditions:
- Depressive Disorder, Major
- Sponsor:
- Janssen Research & Development, LLC
- Who:
- ages 12 Years to 17 Years, 258 participants planned
- Also in:
- Brazil, Hungary, Italy, Romania, Spain, Taiwan
- Boston Childrens Hospital, Boston, Massachusetts
Phase 1PsilocybinNCT07516405
Safety and Tolerability Trial of Psilocybin in Healthy Older Adults (Psil-Pk)
- Conditions:
- Healthy Volunteer; Older Adults (65-85 Years)
- Sponsor:
- University of Colorado, Denver
- Who:
- ages 65 Years to 85 Years, 40 participants planned, accepts healthy volunteers
- Dana-Farber Cancer Institute, Boston, Massachusetts
Phase 4Ketamine / esketamineNCT05450432
Long-Term Maintenance With Ketamine and Esketamine for Reduction of Suicide in High-Risk Patients With Depression
- Conditions:
- Major Depressive Disorder
- Sponsor:
- Massachusetts General Hospital
- Who:
- ages 18 Years to 70 Years, 100 participants planned
- Massachusetts General Hospital, Boston, Massachusetts
Phase 2PsilocybinNCT06001749
Psilocybin in Cancer Pain Study
- Conditions:
- Opioid-Related Disorders; Pain Management; Pain Management and Care; Advanced Cancer; Advanced Cancers
- Sponsor:
- Yvan Beaussant, MD, MSci
- Who:
- ages 18 Years and over, 15 participants planned
- Dana-Farber Cancer Institute, Boston, Massachusetts
Early phase 1MDMANCT06066853
MDMA-assisted Therapy for Fibromyalgia
- Conditions:
- Fibromyalgia
- Sponsor:
- Spaulding Rehabilitation Hospital
- Who:
- ages 21 Years to 65 Years, 20 participants planned
- Massachusetts General Hospital, Charlestown, Massachusetts
Phase 3PsilocybinNCT06247839
The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder
- Conditions:
- Major Depressive Disorder
- Sponsor:
- Sharmin Ghaznavi
- Who:
- ages 18 Years to 55 Years, 20 participants planned
- Athinoula A. Martinos Center for Biomedical Imaging, Charlestown, Massachusetts
Phase 1/2Ketamine / esketamineNCT06597695
A Ketamine-assisted Group Therapy Intervention for Spanish-speaking Adults With Depression
- Conditions:
- Depression
- Sponsor:
- Juliana Zambrano, MD, MPH
- Who:
- ages 18 Years to 64 Years, 10 participants planned
- Massachusetts General Hospital, Chelsea, Chelsea, Massachusetts